SuperNova DiagnosticsÂ® Secures European Partnership with Concile, GmbH and First Commercial Order
WASHINGTON, LONDON and HONG KONG, Nov. 18, 2011 /PRNewswire/ — SuperNova DiagnosticsÃ‚®, Inc., a privately-held global diagnostics company for human and non-human health applications, today announced a commercial partnership with Concile, GmbH, a European Specialist Healthcare Distributor, for a point-of-care test for use in the assessment of various deficiencies relating to wellness and chronic diseases.
Under terms of the agreement, SuperNova will develop and manufacture the point-of-care test product, secure regulatory approvals and co-promote the product in the European market. SuperNova will receive upfront payments, milestone development payments and a revenue-sharing sales deal for all sales in the European Union (EU). SuperNova will retain 100 percent of marketing rights outside of the EU and has the ability to sub-license or sell directly. Other terms of the deal were not disclosed.
Franz Maier, Managing Director of Concile, said, “SuperNova’s technology is a perfect fit to our specially diagnostics business in Europe, and we look forward to adding additional tests to the partnership over the coming year.”
Neil J. Campbell, President & CEO of SuperNova, commented, “The partnership and sales reach of Concile gives us a focused entry into the European market with an established leader and also allows us to build our commercial business into other markets.”
About Concile, GmbH
Concile, GmbH is a leading European developer and distributor of innovative and sophisticated diagnostic products and is known as a specialist in leading edge point-of-care products in Germany and Europe. The company currently sells and develops products in the cardiovascular, oncology, wellness, infectious disease, diabetes, metabolic and esoteric diseases. For more information, please our website at http://www.concile.de/en/home/
About SuperNova DiagnosticsÃ‚®, Inc.
SuperNovaÃ‚® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystalÃ‚®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNovaÃ‚® — Putting the Laboratory in the Palm of Your HandÃ‚®. For additional information, please visit www.supernovadiagnostics.com.
Tiberend Strategic Advisors, Inc.
SOURCE SuperNova Diagnostics(R), Inc.